Naser Abdallah Y, Alwafi Hassan, Alsairafi Zahra
Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University. Amman (Jordan).
Faculty of Medicine. Umm Al Qura University. Mecca (Saudi Arabia).
Pharm Pract (Granada). 2020 Apr-Jun;18(2):1847. doi: 10.18549/PharmPract.2020.2.1847. Epub 2020 May 25.
This study aims to estimate the length of stay and hospitalisation cost of hypoglycaemia, and to identify determinants of variation in the length of stay and hospitalisation cost among individual patients with type 1 or 2 diabetes mellitus.
A cross-sectional study was conducted using inpatients records for patients with diabetes mellitus who had been hospitalised due to hypoglycaemic events in two private hospitals in Amman, Jordan between January 2009 and May 2017. All hospitalisation costs were inflated to the equivalent costs in 2017. Hospitalisation cost was estimated from the patient's perspective in Jordanian dinars (JOD). Descriptive analyses and correlation between sociodemographic or clinical characteristics with the cost and length of stay were explored. Predictors of hypoglycaemic hospitalisation cost and length of stay were determined using logistic regression.
During the study period a total of 126 patients with diabetes mellitus were hospitalised due to an incident of hypoglycaemia. The mean patient age was 64.2 (SD=19.6) years; half were male. Patients admitted for hypoglycaemia stayed in hospital for a median duration of two days (IQR=2 days). The median cost of hospitalisation for hypoglycaemia was 163.2 JOD (USD 230.1) (IQR=216.3 JOD). We found that the Glasgow coma score was positively associated with length of stay (0.345, p=0.008), and older age was correlated with higher hospitalisation cost (0.207, p=0.02). Patients with a family history of diabetes had higher hospitalisation costs and longer duration of stay (0.306 and 0.275, p<0.05). In addition, being a male patient (0.394, p<0.05) and with an absence of smoking history was associated with longer duration of stay (0.456, p<0.01), but not with higher hospitalisation cost.
Costs associated with the incidence of hypoglycaemic events are not low and constitute a large cost component of managing and treating diabetes mellitus. Male patients and patients having a family history of diabetes should receive extra care and education on the prevention of hypoglycaemic events, and a treatment de-intensification approach should be considered if necessary, so we can prevent its associated hospitalisation costs and length of stay.
本研究旨在估算低血糖症的住院时长和住院费用,并确定1型或2型糖尿病个体患者住院时长和住院费用差异的决定因素。
采用横断面研究,使用2009年1月至2017年5月在约旦安曼两家私立医院因低血糖事件住院的糖尿病患者的住院记录。所有住院费用均折算为2017年的等效费用。从患者角度以约旦第纳尔(JOD)估算住院费用。探索社会人口统计学或临床特征与费用和住院时长之间的描述性分析及相关性。使用逻辑回归确定低血糖住院费用和住院时长的预测因素。
在研究期间,共有126例糖尿病患者因低血糖事件住院。患者平均年龄为64.2(标准差=19.6)岁;一半为男性。因低血糖入院的患者中位住院时长为两天(四分位间距=2天)。低血糖住院的中位费用为163.2约旦第纳尔(230.1美元)(四分位间距=216.3约旦第纳尔)。我们发现格拉斯哥昏迷评分与住院时长呈正相关(0.345,p=0.008),年龄较大与住院费用较高相关(0.207,p=0.02)。有糖尿病家族史的患者住院费用较高且住院时间较长(0.306和0.275,p<0.05)。此外,男性患者(0.394,p<0.05)且无吸烟史与住院时间较长相关(0.456,p<0.01),但与住院费用较高无关。
与低血糖事件发生相关的费用不低,构成糖尿病管理和治疗的一大成本组成部分。男性患者和有糖尿病家族史的患者应在预防低血糖事件方面接受额外护理和教育,如有必要应考虑采用治疗强化降低的方法,以便我们能够预防其相关的住院费用和住院时长。